{
  "alleleExist":false,
  "dataVersion":"v4.5",
  "diagnosticImplications":[],
  "diagnosticSummary":"",
  "geneExist":true,
  "geneSummary":"STK11, a tumor suppressor and intracellular kinase, is frequently mutated in lung cancer.",
  "highestDiagnosticImplicationLevel":null,
  "highestFdaLevel":"LEVEL_Fda3",
  "highestPrognosticImplicationLevel":null,
  "highestResistanceLevel":null,
  "highestSensitiveLevel":"LEVEL_4",
  "hotspot":false,
  "lastUpdate":"12/21/2021",
  "mutationEffect":{
    "citations":{
      "abstracts":[],
      "pmids":[
        "24652667",
        "19892943",
        "25079552",
        "21516316",
        "19340305"
      ]
    },
    "description":"STK11 frameshift, nonsense, or splice site mutations result in a truncated and inactive protein product and occur most commonly located within the kinase domain (PMID: 24652667). Truncating mutations of STK11 tend to be somatic and biallelic resulting in truncated protein products (PMID: 21516316). These mutations are common in lung adenocarcinoma (PMID: 25079552), and to a lesser frequency in cervical cancer (PMID: 19340305). Studies show truncating mutations affect the ability of STK11 to bind to cofactor magnesium ions resulting in kinase inactivity (PMID: 19892943), and may also affect targeted drug sensitivities.",
    "knownEffect":"Likely Loss-of-function"
  },
  "oncogenic":"Likely Oncogenic",
  "otherSignificantResistanceLevels":[],
  "otherSignificantSensitiveLevels":[],
  "prognosticImplications":[],
  "prognosticSummary":"",
  "query":{
    "alteration":"P281Rfs*6",
    "alterationType":null,
    "consequence":"frameshift_variant",
    "entrezGeneId":6794,
    "hgvs":"19:g.1221315del",
    "hugoSymbol":"STK11",
    "id":null,
    "proteinEnd":279,
    "proteinStart":279,
    "referenceGenome":"GRCh38",
    "svType":null,
    "tumorType":null
  },
  "treatments":[
    {
      "abstracts":[
        {
          "abstract":"Li et al. Abstract # 602, JITC 2021",
          "link":"https://jitc.bmj.com/content/9/Suppl_2/A632.altmetrics"
        }
      ],
      "alterations":[
        "Oncogenic Mutations"
      ],
      "approvedIndications":[],
      "description":"Bemcentinib is an inhibitor of the AXL receptor tyrosine kinase, and pembrolizumab is an anti-PD-1 antibody. In a phase II trial of bemcentinib + pembrolizumab in patients with advanced non-small cell lung cancer (NSCLC), three evaluable patients with STK11 mutations demonstrated objective clinical response/clinical benefit. Additionally, preclinical data shows that AXL inhibition increases the efficacy of checkpoint blockade in STK11-deficient tumor models (Abstract: Li et al. Abstract # 602, JITC 2021. https://jitc.bmj.com/content/9/Suppl_2/A632.altmetrics).",
      "drugs":[
        {
          "drugName":"Bemcentinib",
          "ncitCode":"C121854",
          "synonyms":[],
          "uuid":null
        },
        {
          "drugName":"Pembrolizumab",
          "ncitCode":"C106432",
          "synonyms":[],
          "uuid":null
        }
      ],
      "fdaLevel":"LEVEL_Fda3",
      "level":"LEVEL_4",
      "levelAssociatedCancerType":{
        "children":{},
        "code":"",
        "color":"Gainsboro",
        "id":876,
        "level":0,
        "mainType":{
          "id":null,
          "name":"Non-Small Cell Lung Cancer",
          "tumorForm":"SOLID"
        },
        "name":"",
        "parent":null,
        "tissue":"Lung",
        "tumorForm":"SOLID"
      },
      "levelExcludedCancerTypes":[],
      "pmids":[]
    }
  ],
  "tumorTypeSummary":"",
  "variantExist":false,
  "variantSummary":"The STK11 P281Rfs*6 mutation is likely oncogenic.",
  "vus":false
}